Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology

References

• Abel EL. Marijuana, the first 12,000 years. In: Cannabis in the ancient world. Springer Science+Business Media, New York: Plenum Press; 1980. p. 3–35.
   Google Scholar
• National Academies of Sciences. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.
   Google Scholar
• Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – regulation in Europe and North America. Eur J Intern Med. 2018;49:2–6.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011–2020.
   PubMed Web of Science ®Google Scholar
• Yeshurun M, Shpilberg O, Herscovici C, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015;21:1770–1775.
   PubMed Web of Science ®Google Scholar
• Naftali T, Mechulam R, Lev LB, et al. Cannabis for inflammatory bowel disease. Dig Dis. 2014;32:468–474.
   PubMed Web of Science ®Google Scholar
• Shevyrin V, Melkozerov V, Endres GW, et al. On a new cannabinoid classification system: a sight on the illegal market of novel psychoactive substances. Cannabis Cannabinoid Res. 2016;1:1, Mini-review
   PubMedGoogle Scholar
• Bar-Sela G, Avisar A, Batash R, et al. Is the clinical use of cannabis by oncology patients advisable? Curr Med Chem. 2014;21(17):1923–1930.
   PubMed Web of Science ®Google Scholar
• Curran HV, Freeman TP, Mokrysz C, et al. Keep off the grass? Cannabis, cognition and addiction [Review]. Nat Rev Neurosci. 2016;17(5):293–306.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–784.
   PubMed Web of Science ®Google Scholar
• Alexander SP, Christopoulos A, Davenport AP, et al. Concise guide to pharmacology 2017/2018: G protein-coupled receptors. Br J PHarmacol. 2017;174(Suppl 1):S17–S129.
   PubMedGoogle Scholar
• Ttsuboi K, Uyama T, Okamoto Y, et al. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm Regen. 2018;38:28.
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Ware MA, Müller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45(3):199–210.
   PubMed Web of Science ®Google Scholar
• Martin JH, Schneider J, Lucas CJ, et al. Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction? Clin Pharmacokinet. 2018;57(5):539–545.
   PubMed Web of Science ®Google Scholar
• Lanz C, Mattsson J, Soydaner U, et al. Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PLoS One Public Lib Sci. 2016;11:e0147286.
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliat Care Pharmacother. 2014;28:216–225.
   PubMedGoogle Scholar
• Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–774.
   PubMed Web of Science ®Google Scholar
• Himmi T, Dallaporta M, Perrin J, et al. Neuronal responses to delta 9-tetrahydrocannabinol in the solitary tract nucleus. Eur J Pharmacol. 1996;312(3):273–279.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Antiemesis (version 3.2018) https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf Last accessed April 25, 2018.
   Google Scholar
• Machado RFC, Stefano SC, Haiek RC, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17(5):431–443.
   PubMed Web of Science ®Google Scholar
• Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16–21.
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1–2):1–25.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
   PubMed Web of Science ®Google Scholar
• Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symp Manage. 1991;6(6):352–359.
   PubMed Web of Science ®Google Scholar
• Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533–543.
   PubMed Web of Science ®Google Scholar
• Duran M, Perez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70:656–663.
   PubMed Web of Science ®Google Scholar
• Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav. 2006;87(1):66–71.
   PubMed Web of Science ®Google Scholar
• Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain [Review]. Rambam Maimonides Med J. 2013;4(4):e0022.
   PubMedGoogle Scholar
• Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474–2483.
   PubMed Web of Science ®Google Scholar
• Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167(5):319–331.
   PubMed Web of Science ®Google Scholar
• Noyes R Jr, Brunk SF, Avery DA, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18(1):84–89.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–449.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–218.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Vorobeichik M, Drawsheh S, et al. The medical necessity for medicinal cannabis: prospective, observational study evaluating treatment in cancer patients on supportive or palliative care. Evid Based Complement Alternat Med. 2013; 2013: 510392.
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10(2):89–97.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol. 2002;20(2):567–573.
   PubMed Web of Science ®Google Scholar
• Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the cannabis-in-cachexia-study-group. J Clin Oncol. 2006;24(21):3394–3400.
   PubMed Web of Science ®Google Scholar
• Brisbois TD, de Kock IH, Watanabe SM. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22(9):2086–2093.
   PubMed Web of Science ®Google Scholar
• Velasco G, Hernandez-Tiedra S, Davila D, et al. The use of cannabinoids as anticancer agents [Review]. Prog. Neuro-Psychopharmacol. Biol Psychiatry. 2016;64:259–266.
   Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.
   PubMed Web of Science ®Google Scholar
• Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004;64:1943–1950.
   PubMed Web of Science ®Google Scholar
• DeMorrow S, Glaser S, Francis H, et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem. 2007;282:13098–13113.
   PubMed Web of Science ®Google Scholar
• Takeda S, Okajima S, Miyoshi H, et al. Cannabidiolic acid, a major cannabinoid in fber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett. 2012;214(3):314–319.
   PubMed Web of Science ®Google Scholar
• Liu WM, Scott KA, Shamash J, et al. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma. 2008;49(9):1800–1809.
   PubMed Web of Science ®Google Scholar
• Pagano E, Borrelli F. Targeting cannabinoid receptors in gastrointestinal cancers for therapeutic uses: current status and future perspectives. Expert Rev Gastroenterol Hepatol. 2017;11(10):871–873.
   PubMed Web of Science ®Google Scholar
• Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014;5(15):5852–5872.
   PubMedGoogle Scholar
• Caffarel MM, Andradas C, Mira E, et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010;9:196.
   PubMed Web of Science ®Google Scholar
• Preet A, Qamri Z, Nasser MW. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res Phila. 2011;4(1):65–75.
   PubMed Web of Science ®Google Scholar
• Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signaling pathways and activate proapoptotic function of Bad protein. Cell Signal. 2005;17(1):25–37.
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 2006;281(51):39480–39491.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Wattez N, et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56(1):1–12.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66(13):6748–6755.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Lorente M, Egia A, et al. The stress-regulated protein p8 mediates cannabinoid- induced apoptosis of tumor cells. Cancer Cell. 2006;9(4):301–312.
   PubMed Web of Science ®Google Scholar
• Gustafsson K, Sander B, Bielawski J, et al. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res. 2009;7(7):1086–1098.
   PubMed Web of Science ®Google Scholar
• Dando I, Donadelli M, Costanzo C, et al. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis. 2013;4:e664.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129(1):37–47.
   PubMed Web of Science ®Google Scholar
• Murase R, Kawamura R, Singer E, et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol. 2014;171:4464–4477.
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Murase R, Limbad C, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013;73(5):1559–1569.
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst. 2008;100(1):59–69.
   PubMedGoogle Scholar
• Ravi J, Sneh A, Shilo K, et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget. 2014;5(9):2475–2486.
   PubMedGoogle Scholar
• Elbaz M, Ahirwar D, Ravi J, et al. Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. Oncotarget. 2017;8:29668–29678.
   PubMedGoogle Scholar
• Fraguas-Sanchez AI, Martin-Sabroso C, Torres-Suarz AI. Insights into the effects of the endocannabinoid system in cancer: a review. Br J Pharmacol. 2018;175(13):2566–2580.
   PubMed Web of Science ®Google Scholar
• Gustafsson SB, Wallenius A, Zackrisson H, et al. Effects of cannabinoids and related fatty acids upon the viability of P19 embryonal carcinoma cells. Arch Toxicol. 2013;87(11):1939–1951.
   PubMed Web of Science ®Google Scholar
• Aguado T, Carracedo A, Julien B, et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem. 2007;282(9):6854–6862.
   PubMed Web of Science ®Google Scholar
• Fiore D, Ramesh P, Proto MC, et al. Rimonabant kills colon cancer stem cells without inducing toxicity in normal colon organoids. Front Pharmacol. 2017;8:949.
   PubMed Web of Science ®Google Scholar
• Scott KA, Dalgleish AG, Liu WM. Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. Int J Oncol. 2017;51:369–377.
   PubMed Web of Science ®Google Scholar
• Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011;2:e152.
   PubMed Web of Science ®Google Scholar
• Miyato H, Kitayama J, Yamashita H, et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res. 2009;155:40–47.
   PubMed Web of Science ®Google Scholar
• Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008;591:128–131.
   PubMed Web of Science ®Google Scholar
• Holland ML, Panetta JA, Hoskins JM, et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71:1146–1154.
   PubMed Web of Science ®Google Scholar
• Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 2014;13(12):2955–2967.
   PubMed Web of Science ®Google Scholar
• Eisenstein TK. Effects of cannabinoids on T‐cell function and resistance to infection. J Neuroimmune Pharmacol off J Soc Neuroimmune Pharmacol. 2015;10:204–216.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta 9 tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281–3289.
   PubMed Web of Science ®Google Scholar
• Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165:373–380.
   PubMed Web of Science ®Google Scholar
• Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197–203.
   PubMed Web of Science ®Google Scholar
• Foroughi M, Hendson G, Sargent MA, et al. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas – possible role of Cannabis inhalation. Childs Nerv Syst. 2011;27:671–679.
   PubMed Web of Science ®Google Scholar
• Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol. 2013;6:585–592.
   PubMedGoogle Scholar
• Twelves C, Short S, Wright S. A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM). 15_suppl.2046. J clin oncol. 2017 May 20;35(15_suppl):2046.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Aug 11. Identifier NCT01812603.  A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma. Last accessed Apr 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT01812603
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Feb 9 . Identifier NCT01489826. A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours. Cited on April 25, 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT01489826?cond=dexanabinol+cancer&rank=3
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 July 7. Identifier NCT01654497. Dexanabinol in Patients with Brain Cancer. Cited on April 25, 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT01654497?cond=dexanabinol+cancer&rank=1
   Google Scholar
• Taha T, Talhamy S, Wollner M, et al. Abstract 1545PD: the effect of cannabis use on tumor response to nivolumab in patients with advanced malignancies. Ann Oncol. 2017 September 1;28(Issue suppl_5): mdx388.005.
   Google Scholar
• Hoch E, Bonnet U, Thomasius R, et al. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015;112:271–278.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Tauber D, Mitnik I, et al. Abstract: cannabis-related cognitive impairment: prospective evaluation of possible influences on cancer patients during chemotherapy treatment. MASCC/ISSO 2018 e-poster.
   Google Scholar
• Callaghan RC, Allebeck P, Akre O, et al. Cannabis use and incidence of testicular cancer: a 42-year follow-up of Swedish men between 1970 and 2011. Cancer Epidemiol Biomarkers Prev. 2017;26:1644–1652.
   PubMed Web of Science ®Google Scholar